| Program | Mechanism of Action (Modality) |
Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
HS-110 |
gp96 + CTAs (Cell Therapy) |
NSCLC |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
HS-130 |
OX40L (Cell Therapy) |
SOLID TUMORS |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
COVID-19 / Biodefense Initiative |
gp96+Pathogen-Derived Antigens (Cell Therapy) |
Infectious Disease |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
PTX-35 |
TNFRSF25 (Antibody) |
SOLID TUMORS |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
CTA = Cancer testis antigens; NSCLC = Non-small cell lung cancer